Search results for: Chronic Diseases

OHE Lunchtime Seminar: Health Technology Assessment Scientific and Outcomes Advice on Medicinal Drug Development

23 August 2016

…medicines and medicines used in orphan diseases. The role of outcomes advice in HTA is not well understood, yet is equally important. The seminar will involve three panellists, all of…

New OHE Consulting Report: Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products: Is the NICE Approach Fit for Purpose?

16 February 2017

…the expectation that that they may bring substantial clinical gains and offer cures for previous debilitating and fatal diseases. However, securing reimbursement is a significant hurdle for manufacturers for two…

OHE at iHEA Boston 2017: Meet the Team

5 July 2017

…to sacrifice some health gain overall to make treatments for some orphan diseases available, it would not tolerate a situation whereby manufacturers of these drugs made higher profits than those…

Why are Mortality Rates Rising for Middle-Aged White Non-Hispanic Americans? Could it Happen in Europe? 24th Annual Lecture Publication

19 March 2018

…diseases, and drug overdose. States in the US have experienced growing rates of mortality from all of these causes, almost without exception. Deaths from these causes have been rising since…

NICE Recommendation Highlights Role of Social Value Judgements

9 August 2018

…ill, the evidence on preferences for prioritising treatments for rare diseases is less clear-cut. NICE’s own Citizens Council (a panel of members of the public, established to provide advice about…

OHE at ISPOR Europe 2018

…medicines, and the approaches to address them. These challenges risk hindering the availability of life-changing treatments for children with rare diseases. Educational symposium: Indication-based Pricing; Who Wins, Who Loses, and…

“You Don’t Always Get What You Want”: Output Distortion and NHS Waiting Time Targets

18 December 2018

…fell to 18 weeks in 2008. Patients of cancer and cardiovascular diseases should not wait more than two weeks to receive appropriate treatment. Carol Propper and co-authors have previously demonstrated…

OHE Response to Public Consultation on NICE Principles

7 February 2019

…(subject of several previous blog posts, including here) A consulting report examining the way in which treatments for very rare diseases are appraised (subject of a previous blog post) A…

The World Needs Better Drugs for TB. The Center for Global Development and OHE Have a Proposal and We Need your Feedback

5 March 2019

…underinvestment is the distribution of the TB burden. Unlike many other diseases that affect rich and poor countries alike, TB is highly concentrated within large Middle Income Countries (MICs), many…